Assessing Lexeo Therapeutics' Cash Burn: Will It Spend Wisely?

Lexeo Therapeutics, a NASDAQ-listed company, has a cash runway of 22 months as of December 2025, with $182m in cash and no debt. The company's cash burn increased 21% in the last year, and analysts forecast a break-even point in about 3 years. The company's ability to raise more cash and sustain its growth trajectory remains uncertain.